DRKS00031088招募中不适用
Cystectomy register study Klinikum Region Hannover - ZRS
KRH Klinikum Region Hannover0 个研究点目标入组 70 人开始时间: 2023年2月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •- Urothelial carcinoma
- •- Image files available
- •- Existence of tumor conference decision: cystectomy
- •- Primary Operation in the department of the respective center
- •- Ability to consent
排除标准
- •- Known bleeding tendency
- •- Neoadjuvant chemotherapy
- •- Palliative indication
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab for cisplatin-ineligible patients with MIBCEUCTR2018-003809-26-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.610
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab for cisplatin-ineligible patients with MIBCMuscle-invasive Bladder Cancer (MIBC)MedDRA version: 20.0 Level: LLT Classification code 10022877 Term: Invasive bladder cancer System Organ Class: 100000004864EUCTR2018-003809-26-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.610
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab for cisplatin-ineligible patients with MIBCMuscle-invasive Bladder Cancer (MIBC)MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2018-003809-26-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.610
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab for cisplatin-ineligible patients with MIBCEUCTR2018-003809-26-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.610
招募中
不适用
Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR)Invasive Bladder CancerBladder CancerNCT04523025Turku University Hospital230